Long-acting nifedipine in the management of the hypertensive patient

Review

(3647) Views  (675) Full article downloads

Authors: Morgan E Snider, Donald S Nuzum, Angie Veverka

Published Date December 2008 Volume 2008:4(6) Pages 1249 - 1257

DOI: http://dx.doi.org/10.2147/VHRM.S3661

Morgan E Snider¹, Donald S Nuzum², Angie Veverka²

¹Virginia Commonwealth University Health Systems Richmond, VA USA; ²Wingate University School of Pharmacy Wingate, NC USA

Abstract: Hypertension is a global condition affecting billions worldwide. It is a significant contributor to cardiovascular events, cardiac death and kidney disease. A number of medication classes exist to aid healthcare providers and their patients in controlling hypertension. Nifedipine, a dihydropyridine calcium channel blocker, was once one of the most widely used medications for hypertension, but safety and tolerability concerns along with the introduction of new classes of antihypertensive medications and an increasing pool of data showing mortality benefit of other classes caused nifedipine to fall out of favor. More recently, long-acting formulations were developed and made available to clinicians. These newer formulations were designed to address many of the concerns raised by earlier formulations of nifedipine. Numerous clinical trials have been conducted comparing long-acting nifedipine to many of the more commonly prescribed antihypertensive medications. This review will address the pharmacology, pharmacokinetics and the available clinical trial data on long-acting nifedipine and summarize its role in the management of hypertension.

Keywords: nifedipine, calcium channel blockers, hypertension